UHS
Universal Health Services
$142.64
▲ 1.0%Updated Jun 22, 7:15 PM ET
▼ Down 17.6% over the last 12 months
Market Cap
$8.89B
P/E
5.49x
Forward P/E (est.)
4.07x
ROE
21.0%
Revenue Growth
10.4%
EPS Growth
34.8%
Profit Margin
8.6%
FCF Yield
11.9%
Debt / Equity
0.65x
ROIC
13.0%
Interest Coverage
12.78x
Current Ratio
1.08x
Dividend Yield
0.6%
Implied Growth (rev. DCF)
-0.5%
Rating Score
65/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what UHS's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. UHS trades near $142.64, below its 50-day average ($164.00) and 200-day average ($198.03). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 37 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. UHS's is $4.72 (~3.3% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month UHS found buyers near $140.08 (support) and sellers near $167.27 (resistance); its 52-week range is $140.08–$246.33. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.7× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Universal Health Services (UHS) is a mid-cap company in the Health Care Facilities industry, part of the Health Care sector of the S&P 500, with a market value around $8.89B.
In its latest reported year it generated about $17.36B in revenue and $1.49B in net profit.
Our model rates UHS Favorable (65/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
8.3%
Revenue moved from $12.64B in 2021 to $17.36B in 2025, a 8.3% compound annual growth rate. The most recent year grew a steady 10.4% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
—
Operating Margin
11.5%
Net Margin
8.6%
ROE
21.0%
Universal Health Services keeps about 8.6% of each sales dollar as net profit. Return on equity is 21.0% and return on invested capital about 13.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$4.70B
Net Debt
$4.58B
Net Debt / EBITDA
2.3x
Debt / Equity
0.65x
Leverage: debt-to-equity is 0.7x, and operating profit covers interest about 12.8x, with a current ratio of 1.1x. That is a moderate, manageable debt load for most businesses. It carries roughly $4.70B of total debt against $119.03M of cash.
Operating CF
$1.86B
Free Cash Flow
$849.25M
FCF Margin
4.9%
In the latest year Universal Health Services produced about $1.86B of operating cash flow and $849.25M of free cash flow after capital spending. That is a free-cash-flow yield of about 11.9% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
5.49x
P/S
0.5x
P/B
1.8x
EV / EBITDA
5.52x
UHS trades at 5.5x trailing earnings (about 4.1x on estimated forward earnings), 0.5x sales, and 1.8x book value. Reverse-engineering today's price implies the market expects roughly -0.5% long-term free-cash-flow growth. That is an undemanding multiple — potentially cheap if the business is stable.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How UHS stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), UHS ranks #13 of 59 by our overall rating. It trades at a discount versus the sector on earnings (5.5x P/E vs. 25.4x median) with a higher return on equity (21.0% vs. 14.9%) and faster revenue growth (10.4% vs. 7.9%).
P/E vs sector
5.5x
median 25.4x
ROE vs sector
21.0%
median 14.9%
Growth vs sector
10.4%
median 7.9%
Sector rank
#13
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
The case for UHS:
- Revenue is growing 10.4% a year, a sign of real demand.
- Strong return on equity (21.0%) shows capital is put to work well.
- Healthy free-cash-flow yield (~11.9%) funds buybacks and dividends.
- Our model's overall read is Favorable (65/100).
The case against UHS:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Universal Health Services is a mid-cap health care business still growing nicely, with modest profitability, and a sound balance sheet. It trades at 5.5x earnings, which our model scores Favorable (65/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.